About Axon Medical Technologies 
Michael Zarreii serves as the Chief Executive Officer and Chief Scientific Officer at Axon Medical Technologies, leveraging over 25 years of leadership in executive management, technological innovation, and medical research. His achievements encompass multiple patents across technology and medical fields, alongside prestigious accolades such as a nomination for “Innovator of the Year” by Electronics Design News (EDN) magazine.
The name Intellig-EYES is a tribute to Michael Zarreii’s late daughter, Samira Elizabeth, who tragically passed away from cardiac arrest at the age of 26. Samira was an early supporter of her father’s research and played a pivotal role in naming the platform and contributing to its initial creative designs.
The Axon Medical Technologies Story
In 2003, Zarreii embarked on an entrepreneurial journey driven by philanthropy, aiming to uncover the link between the human brain’s involuntary sensory functions and their influence on cognition and learning. The overarching vision then, as it remains today, is that solving these complex challenges through new discoveries will lead to the development of advanced diagnostic and therapeutic devices, benefiting millions of lives. However, these ambitious goals required years of dedicated effort to achieve.
The research proved to be exceptionally challenging due to its groundbreaking use of non-invasive methods to map the performance of 85% of neurons in the human brain. This innovative approach had limited prior research, necessitating significant efforts to navigate through manufacturing and regulatory obstacles.
After 19 years of dedicated work, Axon Medical’s efforts have finally borne fruit. Recognizing the potential of Axon Medical’s products to benefit injured service members, the U.S. Army has committed funding for a four-year study. This initiative aims to integrate the Intellig-EYES and ECAT platforms into diverse medical treatment protocols, both on battlegrounds and in hospitals.
Risks and Challenges
Undertaking such extensive research for 19 years without government grants was a monumental challenge. Zarreii and a group of dedicated supporters invested millions of dollars to advance the science and develop products that are fully automated, non-invasive, lightweight, portable, accurate, cost-effective, easily accessible, and capable of generating clear, precise reports.
To mitigate risks, Zarreii pursued an extensive understanding of neurology and the current leading treatments for patients affected by neurological deficits targeted by Axon Medical’s products. In 2017, he enrolled in the NYU School of Medicine to earn continuing medical education credits in neurology. Recognizing the importance of expert guidance, Zarreii also prioritized assembling a top-tier advisory board for Axon Medical. This effort led to securing key figures such as the chief medical officer of the NCAA, several colonels serving as U.S. Army medical research doctors, and esteemed physicians from various universities. These professionals generously contribute their expertise to Axon Medical’s advisory board on a voluntary basis.
Innovative Approaches
Axon Medical’s innovative advanced pupillometry approach to measure changes in the performance of autonomic nervous system cranial nerves II, III, VI, and VIII using non-invasive methods necessitated advancements in optics, stimuli generation, and the establishment of measurement standards that were previously non-existent. These pioneering technologies have yielded multiple patents, with additional patents pending approval.
Another innovative aspect was the system’s design, incorporating remote operational control and a leasing model instead of direct sales. Axon Medical aimed to minimize financial implementation risks for healthcare providers by leasing devices at a nominal fee and charging based on patient scans. The technology includes CPT codes for reimbursement by Medicare and other Health insurance carriers, ensuring providers can achieve immediate profitability upon adoption.
Company Initiatives
Future Plans and Culture
